The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antibody-mediated blockade of gremlin-1 in combination with gemcitabine or MEK inhibition in a genetically engineered mouse model of pancreatic cancer.
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Bayer (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Owkin (Inst); Pfizer (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Sotio (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre; Roche
Other Relationship - Genmab (Inst)
 
Paul Jones
Employment - UCB
Stock and Other Ownership Interests - UCB
Patents, Royalties, Other Intellectual Property - UCB
 
Saadia Karim
No Relationships to Disclose
 
Lynsey McKenzie
No Relationships to Disclose
 
Kay Kong
No Relationships to Disclose
 
Jen Morton
Research Funding - AstraZeneca (Inst); Avacta Life Sciences (Inst); Cancer Research Horizons (Inst); Redex (Inst)
Other Relationship - Laverock Therapeutics
(OPTIONAL) Uncompensated Relationships - Laverock Therapeutics
 
Gareth Davies
Employment - Sitryx Therapeutics Limited; UCB
Patents, Royalties, Other Intellectual Property - Ginisortamab
 
Tania Rowley
Employment - UCB
Stock and Other Ownership Interests - UCB